FIELD: medicine.
SUBSTANCE: present invention relates to use of a gel composition, comprising melatonin or a derivative thereof in a proportion of 2.5 % to 5 % w/v for treating and/or preventing mucositis, said gel composition is locally administered in the mucosal surface. Mucositis is preferably caused by radiotherapy and/or chemotherapy, and is preferably oral mucositis.
EFFECT: technical result is lower level oxidative stress in mitochondria, that ensures complete prevention of stomatitis.
12 cl, 17 dwg
Title | Year | Author | Number |
---|---|---|---|
COMBINATION FOR RADIATION- OR CHEMOTHERAPY-INDUCED MUCOSITIS | 2010 |
|
RU2570754C2 |
METHOD FOR PREVENTING RADIATION ORAL MUCOSITIS IN MICE | 2024 |
|
RU2839522C2 |
ANTISEPTIC COMPOSITION INTENDED FOR APPLICATION IN ORAL CAVITY, FOR TREATMENT OF ORAL MUCOSITIS | 2013 |
|
RU2640301C2 |
NOVEL PEPTIDES AND ANALOGS FOR USE IN THE TREATMENT OF ORAL MUCOSITIS | 2014 |
|
RU2668963C2 |
METHODS OF TREATING AND PREVENTING MUCOSITIS BY ANTHOCYANIDIN DERIVATIVES | 2007 |
|
RU2438693C2 |
COMPOSITIONS FOR PREVENTING OR TREATING ACUTE RADIATION SICKNESS | 2018 |
|
RU2841262C2 |
ANTI-INFLAMMATORY AGENT | 2018 |
|
RU2738845C1 |
GASTROINTESTINAL PROLIFERATIVE FACTOR AND ITS APPLICATIONS | 2005 |
|
RU2343158C2 |
PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INTESTINAL MUCOSA INFLAMMATORY DISEASES ON THE BASIS OF LACTOBACILLUS BREVIS 47f STRAIN, MANIFESTING A LOCAL ANTI-INFLAMMATORY ACTIVITY | 2018 |
|
RU2675110C1 |
TREATMENT OF MUCOSAL DAMAGES USING HYALURONAN DELIVERED FROM ADHERING LOZENGE | 2014 |
|
RU2693384C2 |
Authors
Dates
2016-10-20—Published
2012-10-18—Filed